Cardiff Oncology, Inc. — Director's Dealing 2018

Jul 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Trovagene, Inc. (TROV)
CIK: 0001213037
Period of Report: 2018-07-24

Reporting Person: Erlander Mark (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-24	Restricted Stock Units	$	A	45000	Acquired		Common Stock (45000)	Direct

Footnotes

F1: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock.

F2: 7,500 of the RSUs will vest on each of October 1, 2018, January 1, 2019, April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020.